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Abstract: Plasma membrane calcium ATPases (PMCA) are key proteins in the maintenance of
calcium (Ca2+) homeostasis. Dysregulation of PMCA function is associated with several human
pathologies, including neurodegenerative diseases, and, therefore, these proteins are potential drug
targets to counteract those diseases. Gold compounds, namely of Au(I), are well-known for their
therapeutic use in rheumatoid arthritis and other diseases for centuries. Herein, we report the abil-
ity of dichloro(2-pyridinecarboxylate)gold(III) (1), chlorotrimethylphosphinegold(I) (2), 1,3-bis(2,6-
diisopropylphenyl)imidazol-2-ylidenegold(I) chloride (3), and chlorotriphenylphosphinegold(I) (4)
compounds to interfere with the Ca2+-ATPase activity of pig brain purified PMCA and with mem-
branes from SH-SY5Y neuroblastoma cell cultures. The Au(III) compound (1) inhibits PMCA activity
with the IC50 value of 4.9 µM, while Au(I) compounds (2, 3, and 4) inhibit the protein activity with
IC50 values of 2.8, 21, and 0.9 µM, respectively. Regarding the native substrate MgATP, gold com-
pounds 1 and 4 showed a non-competitive type of inhibition, whereas compounds 2 and 3 showed a
mixed type of inhibition. All gold complexes showed cytotoxic effects on human neuroblastoma SH-
SY5Y cells, although compounds 1 and 3 were more cytotoxic than compounds 2 and 4. In summary,
this work shows that both Au (I and III) compounds are high-affinity inhibitors of the Ca2+-ATPase
activity in purified PMCA fractions and in membranes from SH-SY5Y human neuroblastoma cells.
Additionally, they exert strong cytotoxic effects.
Keywords: gold compounds; PMCA; Ca2+-ATPase; calcium homeostasis; SH-SY5Y human
neuroblastoma cells
1. Introduction
Calcium ion (Ca2+) is an essential element in the functioning of several intracellular
processes. This ion regulates several and different metabolic systems, such as photosynthe-
sis, muscle contraction, synaptic plasticity, and apoptosis [1]. Processes of Ca2+ transport
are involved in many cellular activities, namely, division, development, motility, home-
ostasis, stress response, secretion, transport, signaling, and interaction with the host [2,3].
Calcium regulation and fixation is, therefore, critical and necessary, so signaling with
energy costs is essential [2]. The intracellular Ca2+ homeostasis is achieved by channels,
exchangers, and ionic pumps, which are found in cell membranes and/or in sub-cellular
organelles, such as the sarcoplasmic reticulum (SR) or endoplasmic reticulum (ER), Golgi
complex, or mitochondria [4].
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The P-ATPases are characterized by the formation of an aspartyl phosphate interme-
diate during the reaction cycle and can be specific carriers of other ions, such as H+, Na+,
K+, Mg2+, Ag+ and Ag2+, Zn2+, Co2+, Pb2+, Ni2+, and Cu2+, as well as contaminant ion
metals, such as Cd2+ and Hg2+ [5]. Therefore, these ATPases have fundamental roles in
the regulation of all those ions and/or detoxification in the case of contaminating metals.
Regarding Ca2+, there are three types of Ca2+-ATPases involved in Ca2+ homeostasis: the
plasma membrane Ca2+-ATPase (PMCA), which pumps the excess of Ca2+ out of the cell,
and two intracellular pumps that accumulate Ca2+ into the sarco/endoplasmic reticulum
(SERCA) and to the secretory pathway (SPCA), respectively. The three types of pumps
are encoded by separate genes, giving rise to four major PMCA isoforms, three SERCA
isoforms, and two SPCA isoforms [6–8].
Gold is well-known for its biological and medicinal applications, for instance, in
rheumatoid arthritis, antibacterial, antivirus, and anti-parasite activity, as well as in
Alzheimer’s disease [9–15]. In 2013, Au(III) compounds were reported for the first time as
Na+/K+-ATPase inhibitors and, more recently, Au(I,III) compounds were also described
as SERCA inhibitors, both being proposed targets for gold compounds [16–18]. In fact,
the biological activity of these inorganic compounds can be attributed, at least in part, to
the interaction and inhibition of key protein functions, for example, aquaporin, P-type
ATPases, and protein tyrosine phosphatases, among others [16–20]. Some of them, such as
Na+/K+-ATPases and Ca2+-ATPases, are putative pharmacological targets of a substantial
number of drugs, well-known as ion pumps inhibitors [21–25]. Moreover, it has been
shown that the PMCA pump is specifically inhibited by the amyloid-β peptide (Aβ) and
tau [26–28], which are components of senile plaques and neurofibrillary tangles found in
brains affected by Alzheimer’s disease. Those effects were also seen in the PMCA from
neuroblastoma cells membranes [28]. Several diseases, such as neurological illnesses, are
associated with disfunction of SERCA and PMCA. Therefore, their putative inhibition
by compounds used in current therapies should be carefully assessed to finely set their
dosage in order to prevent collateral and unwanted toxic effects on healthy cells. That is
the reason why the search for specific modulators of these P-type ATPases is of upcoming
interest. Some modulators are inhibitors of the Na+/K+-ATPases and Ca2+-ATPases and
could prevent calcium homeostasis changes in case of specific diseases.
For example, lithium, well-known in treatment of bipolar disease, has been recently
described to partially prevent the increase of Na+/K+-ATPase activity induced by sleep
privation, as observed in rats [29]. On the other hand, in humans, lithium showed to be a
Na+/K+-ATPase regulator once it was verified that impede the decreased of the Na+/K+-
ATPase activity observed in Chorea-acanthocytosis patients [30]. However, metal elements
that could be a good choice in the treatment of diseases, but when accumulated in brain,
they can differently affect astrocytes and neurons, inducing cytotoxicity in brain cells [31].
In the present study, we further explore the potential of gold compounds in P-type
ATPases inhibition and, for the first time, in the PMCA activity. Thus, the aims of this work
are (i) to test the brain PMCA activity in the presence of gold complexes 1–4 (Figure 1);
(ii) to characterize the type of Ca2+-ATPase inhibition obtained with these compounds;
and (iii) to test their effects in a widely used in vitro model system, such as the SH-SY5H
human neuroblastoma cell line, in order to compare the functional effects with those found
in the purified brain PMCA. Results indicate that all tested compounds inhibit PMCA
activity. Compounds 1 and 4 showed a non-competitive inhibition, while compounds 2
and 3 produced a mixed inhibition on purified PMCA activity. Gold complexes, at the
assayed concentrations, are shown to be cytotoxic to SH-SY5Y cells, although the degree of
toxicity depended on each gold compound. The fact that gold compounds inhibited the
plasma membrane Ca2+-ATPase activity in purified preparations of pig brain led us to test
an alternative widely used in vitro model system, such as SH-SY5Y neuroblastoma cells, to
corroborate the functional effects of gold compounds found in PMCA from pig brain.
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Figure 1. Structures of the gold complexes used in the study: (1) dichloro (2-pyridinecarboxylate)
gold(III); (2) chlorotrimethylphosphine gold(I); (3) 1,3-bis(2,6-diisopropylphenyl) imidazole-2-ylidene
gold(I) chloride; and (4) chlorotriphenylphosphine gold(I). Formal charge distribution is also shown.
2. Materials and Methods
2.1. Gold Complexes
The gold(I) and gold(III) chemical structures used in this work can be found in Figure 1.
Dichloro(2-pyridinecarboxylate)gold(III) (1) was purchased from Aldrich. The Au(I)
complexes chlorotrimethylphosphinegold(I) (2), 1,3-bis(2,6-diisopropylphenyl)imidazol-
2-ylidenegold(I) chloride (3), and chlorotriphenylphosphinegold(I) (4) (Figure 1, Table 1),
were purchased from Strem Chemicals.
Table 1. Gold compounds used in the present study.
Formula Abbreviation Net Charge MW (g/mol) CAS Number
C6H4NAuCl2O2 1 +3 389.97 88215-41-2
C3H9PAuCl 2 +1 308.50 15278-97-4
C27H36AuClN2 3 +1 621.01 852445-83-1
C18H15PAuCl 4 +1 494.71 14243-64-2
Stock solutions of the gold compounds (10 mM) were freshly prepared by dissolving
the solid compound in 100% of DMSO and keeping the solution at room temperature.
Wherever adequate, the gold compounds solutions freshly prepared were diluted also in
DMSO to 1 and/or 0.1 mM final concentrations before being used in the enzymatic assays.
2.2. Preparation of Purified Synaptosomal PMCA
The PMCA was purified from pig brain as described in Salvador and Mata [32]. Briefly,
fresh cerebrum (~80 g) obtained from a loc l sl ughterhouse was homogenized in 10 vol of
10 mM HEPES/KOH, pH 7.4; 0.32 M sucrose; 0.5 mM MgSO4; 0.1 mM PMSF; a d 2 mM
2-mercaptoethanol. After two centrifugation steps at 1500× g and 20,0 0× g, the pellet
was subjected to 40–20% (w/v) discontinuous sucrose gradient, and sy aptosomes were
obtained at the interface and resuspended in 10 mM HEPES/KOH, pH 7.4, and 0.32 M
sucrose. Synaptosomes were lysed to obtain synaptosomal plasma membranes that were
further solubilized with 0.6% (w/v) Triton X-100 and loaded onto a calmodulin affinity
column. The fraction containing PMCA was eluted free of lipids with a buffer containing
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15% glycerol, 0.06% Triton X-100, and 2 mM EDTA. Protein concentration was determined
by the Bradford method [33].
2.3. Ca2+-ATPase Activity
Steady-state assays of the PMCA activity were measured spectrophotometrically at
37 ◦C, using the coupled enzyme pyruvate kinase/lactate dehydrogenase assay, as de-
scribed elsewhere [26], under the following conditions: 50 mM HEPES (pH 7.4), 100 mM
KCl, 2 mM MgCl2, 5 mM NaN3, 3.16 µM free Ca2+, 0.42 mM phosphoenolpyruvate,
0.22 mM NADH, 28 IU lactate dehydrogenase, and 10 IU pyruvate kinase. Briefly, delipi-
dated purified PMCA (2.5 µg) containing 0.06% Triton X-100 was mixed with 13.32 µg of
phosphatidylcholine type IIS (PCIIS, from Sigma) previously dried under a N2 atmosphere.
The mixture was incubated for 2 min at 37 ◦C and then diluted to 1 mL assay medium.
Activities were measured after subsequent additions of 1 mM ATP (to start the reaction)
and increasing concentrations of gold compounds [26,27]. All experiments were performed
at least in triplicate.
2.4. Neuroblastoma SH-SY5Y Cell Cultures, Cell Viability, and Membrane Preparation to Measure
Ca2+-ATPase Activity
SH-SY5Y human neuroblastoma cells (Sigma-Aldrich, St. Louis, MO, USA) were
seeded in a 96-well-plate (30,000 cells per well) in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2 mM L-glutamine, 100 mU/mL penicillin, 0.1 mg/mL
streptomycin, and 10% heat-inactivated fetal bovine serum (FBS). After 24 h, the FBS was
removed from the wells and gold compounds were added and incubated for 12 h in DMEM
without FBS.
Cell viability was determined using a colorimetric assay [34] based on the reduction
of the yellow tetrazolium MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) by NAD(P)H-dependent oxidoreductase enzymes of viable cells to purple formazan
crystals that can be measured spectrophotometrically. Briefly, MTT solution was dissolved
in phosphate buffer solution to a final concentration of 0.15 mg/mL and, after DMEM
medium removal, 200 µL was added to each well. Plates were maintained in the CO2
incubator for 1 h and then the MTT solution was removed, and 60 µL of DMSO was
added to each well to dissolve the formazan crystals. Absorbance was read at 490 nm with
background subtraction at 650 nm, in a Varioskan Flash fluorescence spectrophotometer
(Thermo Scientific, Waltham, MA, USA). Results were expressed as percentage of the
control (untreated cells).
Activity assays were performed in membranes prepared from SH-SY5Y cell cultures,
incubated in the presence or in the absence of compounds for 12 h, as described above.
After that, cells were scrapped and centrifuged at 1700× g twice. Cell membranes were
obtained as previously described in [35]. Briefly, samples were homogenized using 10 mM
HEPES/KOH, pH 7.4, 0.32 sucrose; 0.5 mM MgSO4; 0.1 mM phenylmethanesulfonyl fluo-
ride; 2 mM 2-mercaptoethanol and protease inhibitor cocktail solution (Roche Diagnostics,
Basel, Switzerland). After that, samples were centrifuged at 1500× g for 10 min, followed
by 100,000× g centrifugation, and pellets were resuspended in 10 mM HEPES/KOH, pH
7.4, 0.32 sucrose. Protein concentration was determined as above. Activity assays were
performed as described in Section 2.3, using the same assay buffer, supplemented with
0.01% saponin (to distort the plasma and intracellular membranes, allowing the access
of substrates to protein molecules). The reaction was started by addition of 1 mM ATP,
followed by the addition of gold compounds at the indicated concentrations. Activities
were determined after subsequent additions of 100 nM Thapsigargin (to inhibit SERCA),
2 µM vanadate (a concentration that selectively inhibits the PMCA), and 3 mM EGTA (to
subtract the contribution of Mg2+-ATPase activity) [27].
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2.5. Statistical Analysis
Calculations of IC50 values were performed using Microsoft Office 365 Excel (2019)
(Microsoft, Redmond, WA, USA). All values shown are presented as averages and standard
deviations of measurements taken from triplicate measurements, using three distinct and
independent Ca2+-ATPase preparations. The statistical significance of the data was assessed
using the Student’s t-test. Differences from controls were considered significant, at p < 0.05.
3. Results
3.1. Inhibition of PMCA Activity by Gold Compounds
The effects of four gold compounds on the activity of the plasma membrane Ca2+-
ATPase (PMCA) were investigated for the first time. Compounds were added to the
assay after triggering the reaction with ATP, as indicated in the Section 2. As shown in
Figure 2, all Au complexes inhibited PMCA activity, depending on the concentration.
The inhibitory capacity of the investigated gold compounds was evaluated by the half
maximal inhibitory concentration (IC50) values, meaning that the inhibitor concentration
induced 50% of Ca2+-ATPase inhibition of the enzyme activity. The IC50 values were
calculated using Microsoft Office 365 Excel (Microsoft, Red-mond, WA, USA), and ranged
from 0.9 ± 0.1 µM to 21 ± 0.1 µM. Gold(I) compounds 2 and 4 showed the lowest IC50
values: 2.8 ± 0.2 and 0.9 ± 0.1 µM, respectively, indicating a higher inhibition. The gold(III)
compound 1 and gold(I) compound 3 exhibited IC50 values in the range of 4.9 ± 0.1 to
21.0 ± 0.1 µM. Thus, the Au(I) complexes 2 and 4 were, respectively, around 6-to 20-fold
more powerful inhibitors of the ATPase activity than compounds 1 and 3 (Table 2).
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Fig re 2. I ibitio of activity by gol co poun s 1, 2, 3, and 4. The Ca2+- ase as
measured spectrophotometrically at 340 nm and 37 ◦C, using the coupled enzyme pyruvate ki-
nase/lactate dehydrogenase assay. The experiments were initiated after the addition of 2.5 µg/mL of
purifed PMCA reconstituted in PCIIS. Data are plotted as means ± SD. The results shown are the
average of triplicate experiments carried out with different preparations.
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Table 2. Km, Vmax, type of inhibition and IC50 values of PMCA inhibition by gold compounds. * p < 0.05 vs. control (without
any compound).
Gold Compound Km (mM) Vmax (µmol·min−1·mg−1) Type of Inhibition IC50 (µM)
0 (µM) 0.172 ± 0.008 1.92 ± 0.1
1 5 (µM) 0.170 ± 0.008 0.763 ± 0.04 * non-competitive 4.9 ± 0.1
2 3 (µM) 0.242 ± 0.012 * 0.847 ± 0.04 * mixed 2.8 ± 0.2
3 21 (µM) 0.262 ± 0.013 * 0.909 ± 0.04 * mixed 21 ± 0.1
4 1 (µM) 0.174 ± 0.008 0.704 ± 0.03 * non-competitive 0.9 ± 0.1
Note that, at these studies, no PMCA incubation with the gold compounds was
performed. The compounds were added to the medium seconds after the reaction was
initiated. Following the addition of the gold compounds, the rates of the reactions in the
presence of different inhibitor concentrations were measured within the following 2–3 min.
The gold compounds are stable for at least up to 30 min, as previously observed, in the
same medium [18]. In fact, compounds were incubated for 30 min with and without the
protein, and the inhibitory effects of the ATPase were the same as without any incubation,
suggesting that the Au compounds are stable and the effects observed can be attributed to
their addition to the medium [18].
The type of inhibition produced by the gold compounds was analyzed at concentra-
tions around the IC50 by starting the reaction with increasing amounts of the substrate ATP
(Figure 3). It was observed that both Au(III) compound 1 and Au(I) compound 4 reduced
the Vmax by 60% and 64%, respectively, without affecting the Km, therefore showing the
effect of non-competitive inhibition (Figure 3, Table 2).
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Figure 3. Lineweaver–Burk plots of Ca2+-ATPase activity in the absence (empty symbols) and in the
presence (filled symbols) of gold compounds 1, 2, 3, and 4, at concentrations of 5, 3, 21, and 1 µM,
respectively. The plots were used to determine the type of PMCA inhibition. The gold complexes 1
and 4 presented a non-competitive type of inhibition, while compounds 2 and 3 showed a mixed type
of inhibition. Data are plotted as means ± standard deviation. The results shown are the average of
triplicate experiments carried out in distinct preparations.
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On the other hand, both Au(I) complexes 2 and 3 decreased the Vmax by 56% and
53%, respectively, and increased the Km by 41% and 52%, respectively, which is indica-
tive of a mixed type inhibition (Figure 3, Table 2). Thus, it can be suggested that both
Au(I) compounds 2 and 3 interact with two binding sites of PMCA, one being the ATP
binding site.
3.2. Cytotoxic Effects of Gold Compounds in SH-SY5Y Cells
The effects of gold compounds were also evaluated in the human neuroblastoma
SH-SY5Y cell line in order to see if they could affect cell viability (Figure 4). The relative
cell viability was calculated as the percentage of untreated cells (100% viability). Thus,
cells treated with 5 µM of compounds 1 and 3 gave the highest cell viability, with values of
69.30 ± 3.06% and 42.85 ± 4.89%, respectively. Nonetheless, cell survival was significantly
reduced to 6.50 ± 0.66% when treated with 20 µM of compound 3. When cells were treated
with compounds 2 and 4, at a concentration of 5 µM, viability values of 5.73 ± 0.33% and
4.91 ± 0.61%, respectively, were obtained. Regarding this decrease, our results also showed
that viability of cells treated with 4% DMSO alone (which is the percentage of this solvent
in compound 3 at 20 µM) was significantly decreased down to 9.24 ± 0.72%, suggesting
that this reduction could be mostly associated to the toxicity of DMSO. On the contrary,
cells incubated with 0.5% and 1% DMSO alone (which were the percentages of solvent in
1 µM and 5 µM of gold compounds, respectively) did not show any significant toxicity, the
cell viability being 98.75 ± 2.86% and 95.97 ± 6.51%, respectively.
Metals 2021, 11, x FOR PEER REVIEW 7 of 14 
 
 
and 4 presented a non-competitive type of inhibition, while compounds 2 and 3 showed a mixed 
type of inhibition. Data are plotted as means ± standard deviation. The results shown are the av-
erage of triplicate experiments carried out in distinct preparations. 
On the other hand, both Au(I) complexes 2 and 3 decreased the Vmax by 56% and 
53%, respectively, and increased the Km by 41% and 52%, respectively, which is indicative 
of a mixed type inhibition (Figure 3, Table 2). Thus, it can be suggested that both Au(I) 
compounds 2 and 3 interact with two binding sites of PMCA, one being the ATP binding 
site. 
3.2. Cytotoxic Effects of Gold Compounds in SH-SY5Y Cells 
The effects of gold compounds were also evaluated in the human neuroblastoma 
SH-SY5Y cell line in order to see if they could affect cell viability (Figure 4). The relative 
cell viability was calculated as the percentage of untreated cells (100% viability). Thus, 
cells treated with 5 µM of compounds 1 and 3 gave the highest cell viability, with values 
of 69.30 ± 3.06% and 42.85 ± 4.89%, respectively. Nonetheless, cell survival was signifi-
cantly reduced to 6.5  ± 0.66% when treated  0 µM of compound 3. When cells were 
treated with compounds 2 and 4, at a co centration of 5 µM, viability v l s of 5.73 ± 
0.33% and 4.91 ± 0.61%, respectively, were obtained. Regarding this decrease, our results 
also showed that viability of cells treated with 4% DMSO alone (which is the percentage 
of this solvent in compound 3 at 20 µM) was significantly decreased down to 9.24 ± 
0.72%, suggesting that this reduction could be mostly associated to the toxicity of DMSO. 
On the contrary, cells incubated with 0.5% and 1% DMSO alone (which were the per-
centages of solvent in 1 µM and 5 µM of gold compounds, respectively) did not show any 
significant toxicity, the cell viability being 98.75 ± 2.86% and 95.97 ± 6.51%, respectively.  
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Figure 4. Effects of gold compounds on cell viability estimated by the MTT assay. SH-SY5Y cells
were treated ith gold compounds 1, 2, 3, and 4, at the indicated concentrations (in brackets). The
right panel shows viability of cells incubated with 0.5%, %, 4% DMSO alone, which corresponds
to final percentages of the solvent in cell treated with 1, 5, and 20 µM gold compounds, respectively.
Data are expressed as percentage of untreated cells in the absence of DMSO, as mean ± SEM of at
least three independent experiments carried out in triplicate with three different cultures. Symbols (*)
represent significant differences when compared to control (ANOVA, Dunnett’s test, p < 0.05).
3.3. Effects of Gold Compounds on Ca2+-ATPase Activity in SH-SY5Y Cells
The effects of gold compounds on endogenous Ca2+-ATPase activity were also an-
alyzed in membranes prepared from SH-SY5Y neuroblastoma cells. Figure 5A showed
that the Ca2+-ATPase activity of membranes from cells incubated in vitro for 12 h with
compounds 1, 2, and 3, at a concentration of 5 µM, and with compound 4 at 1 µM, de-
creased by 47.31 ± 1.43%, 38.048 ± 1.95%, 66.82 ± 1.46%, and 56.58 ± 1.95%, with respect
to untreated cells. Considering that the degree of ATPase activity inhibition was similar to
the loss of cell viability, we could not rule out that this inhibition was related to the loss
of PMCA protein due to cell death. To experimentally elucidate this question, we also
tested the effects of the compounds in membranes prepared from non-treated cells just by
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adding the compounds after triggering the reaction with ATP. As shown in Figure 5B, the
Ca2+-ATPase activity was also inhibited by all compounds in similar percentages to those
obtained with treated cells, giving values of 35.02 ± 3.30%, 40.52 ± 2.64%, 36.12 ± 0.12%,
and 44.27 ± 4.18% for compounds 1, 2, 3, and 4, respectively. Therefore, we could conclude
that the inhibition of the Ca2+-ATPase by gold compounds was due to modulation of
PMCA by those compounds and not just a consequence of cell death.
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Figure 5. (A) PMCA activity in membrane extracts (10 µg) from SH-SY5Y cells treated with gold
pounds. (B) PMCA activity of non-treated cells b fore and after addition of compounds to the
assay medium, at concentrations of 5, 3, 20, and 1 µM for compounds, 1, 2, 3, and 4, respectively.
Data are expressed as percentage of non-treated cells in the absence of DMSO, as mean ± SEM of at
least three independent experiments carried out in triplicate with three different cultures. Symbols (*)
represent significant differences when compared to control (ANOVA, Dunnett´s test, p < 0.05).
4. Discussion
The Ca2+-ATPase activity was studied in the presence of four gold compounds, either
gold(I) or gold(III), with different ligands, namely, dichloro (2-pyridinecarboxylate) gold(III)
(abbreviated as 1), chlorotrimethylphosphine gold(I) (2), 1,3-bis(2,6-diisopropylphenyl)
imidazole-2-ylidene gold(I) chloride (3), and chlorotriphenylphosphine gold(I) (4) (Figure 1,
Table 1). All tested compounds showed a potent inhibitory effect on PMCA activity. This
pump showed the highest affinity for the inhibitor compound 4, followed by compounds 2,
1, and 3. This inhibitory sequence was like that previously observed in the case of SERCA
protein [18]. The IC50 values obtained in our work with PMCA were similar to those
reported for SERCA, except for compound 2, which presented a lower inhibitory potency
regarding PMCA (IC50 2.8 µM), in comparison with the value (IC50 0.8 µM) obtained for
SERCA [18]. Therefore, these gold(I)-compounds and gold(III)-compounds showed high
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affinity for PMCA and SERCA. Although PMCA and SERCA are P-type ATPases, they
have different features and were previously described to have different sensitivities for
specific P-type ATPases inhibitors, such as polyoxometalates. Herein, only compound 2
present a higher inhibition capacity for SERCA, in comparison with PMCA, which was
about four times more effective, whereas, for the other compounds, the obtained IC50
values were very similar. This means that not all gold compounds can be used as specific
inhibitors for a particular ion pump.
The SERCA vesicle preparations contain mainly the SERCA1 isoform, as analyzed by
SDS-PAGE, although minor amounts of sarcolipin could be found in similar preparations
from other sources. However, to the best of our knowledge, there are no studies stating that
gold compounds bind to this protein known to affect the SERCA function. Therefore, the
results described are only due to the effects on the SERCA ATPase activity and not to the
interference with sarcolipin that, at these experimental conditions, does not affect the hy-
drolytic activity. The model used was previously applied to several inorganic compounds,
including vanadate. In fact, several studies were described about the interaction of organic
and inorganic compounds and their effects on P-type ATPases [23,36–51]. Therefore, sev-
eral experiments with several vanadium compounds [45,47,48] at the same experimental
conditions for comparison were performed, and the potencies of inhibition are compared
in Table 2. In addition, the amyloid-β peptide and tau were used as negative controls,
considering that these two molecular markers of the disease have been reported, by some
of the authors of this work, as inhibitors of the PMCA pump [26–28]. The studies were per-
formed from triplicate measurements, using three distinct and independent Ca2+-ATPase
preparations, as described in the Materials and Methods Section 2.3.
Note that P-type ATPases are well known to be inhibited by metal complexes and com-
pounds [17,22–25], although the structural details of their inhibitory mechanisms remain
unresolved. The non-competitive type of inhibition observed for gold(III) compound 1,
regarding the native substrate MgATP, is in good agreement with previous studies dealing
with SERCA [18] and Na+/K+-ATPase [16]. It was previously described that gold(III)
complexes, H[AuCl4], [Au(DMSO)2Cl2]Cl and [Au(bipy)Cl2]Cl (bipy = 2,2′-bipyridine),
inhibited the enzymatic activity of purified pig brain Na+/K+-ATPase, with IC50 values of
0.57, 5.5, and 39.8 µM, respectively, in a non-competitive mode of interaction [20]. Besides
the non-competitive inhibition observed for gold compounds 1 and 4, a mixed type of
inhibition was also observed for compounds 2 and 3. The type of inhibition found for gold
compounds 1 (non-competitive) and 3 (mixed) for PMCA was similar to the previously
reported results for SERCA [18]. In contrast, gold(I) compounds 2 and 4 inhibited SERCA
through non-competitive and mixed inhibition, respectively [18].
These differences led us to suggest that compounds 1 and 3 may share binding sites
with similar amino acid residues and charge density on PMCA and SERCA, whereas
compounds 2 and 4 could bind to two different sites on SERCA and PMCA. Nevertheless,
for the majority of the gold compounds, the mechanisms of inhibition and the protein
binding sites for P-ATPases remain to be determined [17,25].
It was suggested that gold(III) compounds can bind to the E1 conformation of the
Na+/K+-ATPase [17]. The different binding modes of these gold(III) complexes to the en-
zyme were explained based on their distinctive structural features. In contrast to gold(III),
monomeric vanadate only binds to the E2 conformation of the SERCA, whereas decavana-
date (V10) strongly binds to either E1 or E2 conformations, being phosphorylated or not [44].
However, for the majority of the inorganic compounds described to inhibit P-type ATPases,
the protein conformations and binding sites are still to be determined [17,18,23,25]. In the
near future, protein structural models would help explain such enzymatic results [25,36].
For some drugs, such as thapsigargin (TG) and cyclopiazonic acid (CPA), the mechanisms
of action and ATPases binding sites are clearly established [24].
Polyamines, such as spermine, are potential targets for the development of anti-
cancer drugs and have been shown to inhibit the PMCA pump [37]. Moreover, the
antipsychotic drug thioridazine and other phenothiazine derivatives also inhibit the
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PMCA activity [38]. In the case of SERCA, thapsigargin (IC50 = 0.001–0.029 µM), cy-
clopiazonic acid (IC50 = 0.1–0.2 µM), macrocyclic lactones (IC50 = 66–72 µM), curcumi-
noids (IC50 = 7–17 µM), and celecoxib (IC50 = 35 µM) are examples of well-known in-
hibitors [39–43]. These drugs are used in several disease treatments and are also employed
as anaesthetics, tumour inhibitors, antibiotics, and insulin mimetic agents [39–43], provid-
ing an inhibitory effect not so different from the gold compounds described in the present
study (Table 3).
Table 3. IC50 values and therapeutic applications of the P-type ATPase inhibitors.
Class of Inhibitors Compound IC50 (µM) P-Type ATPase Therapeutical Applications References
Polycation Spermine 2500 PMCA Anticancer [37]
Phenothiazine

































































Sesquiterpene lactone Thapsigargin 0.001–0.029 SERCA Prodrugs for prostate cancertherapy [39]
Indole tetraminic acid Cyclopiazoc acid 0.2–1.0 SERCA Cardioprotective action inmyocardial ischemia [40]
Macrocyclic lactones Cyclosporine ARapamycin
62
77 SERCA Immunossupressant agents [41]
Curcuminoides Curcumin 7–17 SERCA Antioxidants, antitumoral [42]
Celecoxib analog Dimethyl-celecoxib 35 SERCA Anti-inflamatory drug [43]
Herein, we aimed to compare the inhibitory capacity of the gold complexes 1–4 with
oxometalates, metal complexes, and polyoxometalates (POTs and POVs), as well as known
organic drugs. In fact, several inorganic compounds and complexes inhibit Ca2+-ATPases
activity with IC50 inhibition values similar to the well-known Ca2+-ATPases drugs in-
hibitors, for example decavanadate (IC50 = 15 µM), polyoxotungstates (IC50 = 0.3–200 µM),
polyoxovanadates (IC50 = 1 µM), and vanadium complexes, such as BMOV (IC50 = 40 µM),
among others [42–48]. In summary, both gold(I) and gold(III) compounds 1–4 are potent
inhibitors of the PMCA, pointing out this enzyme as a putative target for gold compounds
that are promising agents in medicinal chemistry [49–51].
This work also showed that both Au (I and III) compounds produced a decline in
the viability of SH-SY5Y human neuroblastoma cells, which was dependent on their
structures. In addition, the Ca2+-ATPase activity was also inhibited by the presence of these
compounds. However, the activity results obtained from membranes of treated cells were
comparable to those found with untreated cell membranes, after subsequent addition of
ATP and gold compounds to the assay medium. This similarity suggests that the ATPase
inhibition is also due to an effect of gold compounds on the protein and not only on the
cell viability.
Recently, it was stated that metal contaminants, such as cadmium, induce changes in
biochemical parameters in brain, causing neurological dysfunction in rats [52]. However,
even essential elements, such as cobalt, proved to be accumulated in the brain, inducing
cytotoxicity in SH-SY5Y cells at high concentrations (IC50 = 100.01 ± 5.91 µM, after 72 h
exposure) [31]. Cisplatin compounds have also been reported to induce cytotoxicity on
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SH-SY5Y cells [53]. IC50 values for these platinum compounds of 15–50 µM were observed
using the MTT assay, for an incubation time of 24 h. More recently, high citotoxicity
was reported for this cell line by two gold(I) complexes containing triphenylphosphine
(Au(pben)(PPh3)) (1) or triethylphosphine (Au(pben)(PEt3) (2), showing IC50 values as
low as of 2.7 and 1.6 µM, respectively, after 24 h incubation [54], thus having a similar
order of magnitude to the values described in the present study for other gold (I and
III) compounds.
Altogether, these results suggest that PMCA could be a potential target for the tested
gold compounds. In fact, several pathologies, such as those of a neurological nature,
are linked with SERCA and PMCA disfunctions. Thus, it is important to find specific
modulators of such P-type ATPases that can prevent changes in calcium homeostasis
in some diseases. As discussed above, the putative inhibition of these enzymes by the
compounds can be used in current neurological therapies [12,13]. However, they should be
carefully assessed to finely set their dosage in order to prevent collateral and unwanted
toxic effects of healthy neuron cells such as neurons and astrocytes [14].
It is interesting to note that the scientific community in the 21th century has a vast
knowledge about genes and proteins but the role of essential elements in life remains some-
what limited, not to mention other elements that are apparently not essential. However,
for several metals, and also for gold, the lack of knowledge provides opportunities for
discoveries of applications and/or implications in biochemistry and health.
5. Conclusions
The present study shows that PMCA activity is inhibited by both Au(I) or Au(III)
compounds. Particularly significant inhibition values were found for the Au(I) compound
4 (IC50 < 1 µM), like those previously described for SERCA. A non-competitive type of
inhibition was found for compound 4, which was the most powerful ATPase inhibitor, and
for compound 1, whereas a mixed type of inhibition was observed for compounds 2 and 3,
revealing distinct modes of interaction with PMCA. Both Au (I and III) compounds also
inhibited the endogenous Ca2+-ATPase activity of SH-SY5Y human neuroblastoma cell
lines and affected cell viability, this cytotoxicity being higher for gold compounds 2 and 4.
In summary, we have described the interaction of gold(I,III) compounds with key
cellular proteins such as SERCA and PMCA, from a kinetic point of view. Considering
the importance of gold compounds in inorganic medicinal chemistry, they are very likely
to receive much more attention in the near future as putative inhibitors for several other
key enzymes with biomedical applications. Thus, the application of gold compounds in
biology and biomedical sciences is still a branch in continuous growth.
Author Contributions: Conceptualization: A.M.M. and M.A.; formal analysis: M.B., J.J.C.-G.,
C.G.-M., M.A. and A.M.M.; funding acquisition: A.M.M., C.G.-M. and M.A.; investigation: M.B.,
J.J.C.-G., M.A. and A.M.M.; methodology: M.B., J.J.C.-G., M.A. and A.M.M.; resources: S.A.C.C., M.A.
and A.M.M., supervision: A.M.M. and M.A.; writing—original draft: A.M.M., J.J.C.-G., M.B. and
M.A.; writing—review and editing: A.M.M., M.A., J.J.C.-G., M.B., C.G.-M. and S.A.C.C. All authors
have read and agreed to the published version of the manuscript.
Funding: Projects BFU2017-85723-P (to A.M.M. and C.G.-M.), and PID2020-115512GB-I00 (to A.M.M.)
funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”. We acknowl-
edge Fundação para a Ciência e a Tecnologia (FCT) project UIDB/04326/2020, Associate Laboratory
for Green Chemistry–LAQV, financed by national funds from FCT/MCTES (UIDB/50006/2020 and
UIDP/50006/2020) and Scientific Employment Stimulus-Institutional Call (CEECINST/00102/2018).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Metals 2021, 11, 1934 12 of 14
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or







IC50 Half maximal inhibitory concentration
PDC-V(V) Pyridine-2,6-dicarboxylatodioxovanadium(V)
PMCA Plasmatic membrane calcium ATPase
POTs Polyoxotungstates
PV14O40 Phosphotetradecavanadate
SERCA Sarco(endo) plasmatic membrane calcium ATPase
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